# Gadolinium-cDTPAa conjugated with melanoma monoclonal antibody 9.2.27 as a melanoma specific MRI contrast agent

D. Shahbazi-Gahrouei<sup>1</sup>, M. Williams<sup>1</sup>, S. Rizvi<sup>2</sup>, and B. J. Allen<sup>2</sup>

<sup>1</sup>University of Western Sydney, Nepean and <sup>2</sup>Center for Experimental Radiation Oncology, Cancer Care Center, St. George Hospital, Sydney, Australia

## <u>Introduction</u>

The development of tissue-specific contrast agents deserves considerable attention because of their specificity to the tumor. In recent years, research efforts are concentrated on maximizing the delivery of specific T<sub>1</sub> agents to tumor (1). One approach to increasing the specificity of MR image contrast is to use a monoclonal antibody (McAb) coupled with Gd-DTPA. However, the number of Gd attached to the DTPA-protein complex, the effect of chelation on antibody specificity, and the Gd-DTPA-antibody stability is problematic. The aims of this study are 1) to determine the optimal concentrations for the conjugation of gadolinium and 9.2.27 antibody; 2) to observe the contrast enhancement effect of tissuespecificity with MRI contrast agent-McAb. To this end, the effects of the Gd-DTPA-antibody on the in vitro relaxivity are reported. All samples were tested by inductively coupled plasma atomic emission spectroscopy (ICP-AES) to determine the Gd concentration.

#### Materials and Methods

The McAb 9.2.27 against human melanoma cell lines was conjugated with cyclic anhydride diethylenetriaminepentaacetic acid (cDTPAa) chelating agent as described by Hnatowich et al (2). GdCl<sub>3</sub> (37 mg/mL, Sigma, Aldrich), 10-fold excess of DTPA-McAb, was dissolved in distilled water and added to the cDTPAa-McAb conjugate. The pH was adjusted to 5 by addition of 1 M sodium acetate. After stirring for 1 hour at room temperature, the solution was purified through a sephadex GM-25 column (10 × 1cm) and eluted with sodium chloride (0.15 M, pH = 5).

The melanoma cell line (MM-138, 2.5×10<sup>6</sup> cells/mL) was incubated with Gd-DTPA-9.2.27 for 4 hr at 37 °C. Colorectal cell line (HT-29) was used as a non-specific. After incubation, all the cells were washed twice with PBS/2%FCS, followed by centrifugation, then resuspended in PBS/2%FCS solutions. All samples and solutions were tested by both ICP-AES and NMR.

The relation between relaxation rates versus [Gd] was obtained using solutions of GdCl<sub>3</sub>. T<sub>1</sub> values were obtained on a 7.0 T (Varian *UNITY* Plus) using the saddle coil with a vertical Oxford Instruments magnet of bore size 89 mm. The T<sub>1</sub> was measured using an inversion recovery (IR) pulse sequence with 32 incremental values. The gadolinium content was measured based on an acid digestion procedure using ICP-AES (Applied Research Laboratory, UK) according to the method of Tamat *et al* (3). The 342.249 nm atomic emission line of Gd was chosen for the ICP-AES analysis.

## Results

The data indicate that Gd-cDTPAa-9.2.27 in solution decreased the  $T_1$  relaxation of water protons at 7.0 T in direct proportion to the gadolinium concentration, and this effect was greater than in Gd-DTPA and GdCl<sub>3</sub> solutions. The standard curve shows a very high correlation between inverse  $T_1$  relaxation times and Gd concentration [Gd]. The ICP-AES results showed no Gd in the control HT-29 cells. The relaxivity of Gd-DTPA-9.2.27 were found to be 12.7 mM<sup>-1</sup>s<sup>-1</sup>. Results of  $T_1$  values for different contrast agents in MM-138 and HT-29 are given in table 1.  $T_1$  values decreased (approximately 25%) relative to control.

Table 1. T<sub>1</sub> values of different contrast agents in MM-138 and HT-29 cell lines.

Sample	Cell lines	Initial [Gd] mM	T <sub>1</sub> (msec)
Gd-DTPA-9.2.27	MM-138	50	1250±20
Gd-DTPA-9.2.27	HT-29	50	2500±34
$GdCl_3$	MM-138	5	2060±10
Gd-DTPA	MM-138	5	1550±30
Control	MM-138	-	1850±18
Control	HT-29	-	2800±25
PBS/2%FCS	-	-	3650±12

#### Discussion

The effect of covalently conjugating one (or more) gadolinium ions to a slowly tumbling macromolecule such as an antibody or synthetic protein is to increase the correlation time  $\tau_c$  and enhance relaxivity. Relaxivity enhancements were higher by a factor of 3 or 4 with Gd labeled DTPA protein conjugates than for Gd-DTPA alone. When Gd was conjugated with the 9.2.27 antibody by means of the chelator cDTPAa, a linear relation was observed between the reversal of  $T_1$  relaxation time and the Gd concentration. The enhancing effect of Gd-DTPA-9.2.27 was compared with that of Gd-DTPA. Gd-DTPA-9.2.27 showed significant enhancement effect in melanoma cells compared to Gd-DTPA, controls, and GdCl<sub>3</sub>.

Monoclonal antibodies labeled with gadolinium have been considered in order to effectively targeted the contrast agent to a tumor site. By using a melanomaspecific contrast agent such as Gd-cDTPAa-9.2.27, it may be possible to differentiate between melanoma, tissue damage and radiation injury.

### <u>References</u>

- 1. Goher-Rosental, S. et al, *Invest. Radiol.*, 28(9), 789-795, 1993.
- 2. Hnatowich, D. J. et al, *Int. J .Appl. Radiat. Isot.*, 33, 327-333, 1982.

Tamat, S. R. et al, *Pigment Cell Research*, 2, 281-285, 1989.